Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Tomasini P et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Smolenschi C et al.
Npj Precision Oncology, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Bazhenova L et al.
Clinical Lung Cancer, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients.
Huang Y et al.
Esmo Open, 2025
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
Roles of CDK12 mutations in PCa development and treatment.
Jiang C et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2025
Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.
Mukohara F et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.
Li Y et al.
Hereditary Cancer in Clinical Practice, 2024
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Lung cancer in patients who have never smoked - an emerging disease.
LoPiccolo J et al.
Nature Reviews. Clinical Oncology, 2024
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T et al.
Frontiers in Bioscience (landmark Edition), 2023
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations.
Villani A et al.
Nature Cancer, 2023
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X et al.
Frontiers in Oncology, 2023
Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform.
Banyi N et al.
Current Oncology (toronto, Ont.), 2022
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H et al.
Bmc Cancer, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Coincident pineocytoma and probable brainstem glioma in a child with 22q11.2 deletion syndrome.
Adams JW et al.
Bmj Case Reports, 2022
Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer.
Li N et al.
Annals of Translational Medicine, 2022
Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis.
Cheng CK et al.
Ejhaem, 2022
Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
Li C et al.
Frontiers in Immunology, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Molecular pathogenesis of hereditary lung cancer: a literature review.
Rammal S et al.
Pharmacogenomics, 2021
Higher Mutation Burden in High Proliferation Compartments of Heterogeneous Melanoma Tumors.
Grzywa TM et al.
International Journal of Molecular Sciences, 2021
BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer.
Fan F et al.
Translational Oncology, 2021